Physician profile
Ramesh Krishnamurthi
NPI 1891762365
$3,144.26
in general payments reported to CMS, 2019-2025
24 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $53.01 · 2021: $244 · 2022: $386 · 2023: $921 · 2024: $755 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $655.09 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Boston Scientific Corporation | $628.93 | 2021-2024 | Ams 700, Rezum Generator |
| Endo Pharmaceuticals INC. | $410.23 | 2021-2024 | Xiaflex |
| Coloplast Corp | $337.15 | 2022-2024 | Titan |
| Endo USA, INC. | $132.66 | 2024-2025 | Xiaflex |
| Teleflex LLC | $123.41 | 2025 | Barrigel |
| Astellas Pharma US INC | $123.04 | 2019-2021 | |
| Novo Nordisk INC | $112.77 | 2021 | |
| Ethicon US, LLC | $90.32 | 2025 | Echelon; Endopath |
| Tolmar, INC. | $85.90 | 2023-2025 | Eligard, Jatenzo |
| Convatec INC. | $77.52 | 2022-2023 | |
| Verity Pharmaceuticals INC. | $51.09 | 2025 | Tlando |
| Olympus America INC. | $48.58 | 2023-2025 | Itind System |
| Pfizer INC. | $46.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.66 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.00 | 2019-2020 | |
| Halozyme INC | $21.33 | 2023 | |
| Progenics Pharmaceuticals, INC. | $20.92 | 2023 | Pylarify |
| Sumitomo Pharma America, INC. | $19.50 | 2023 | Gemtesa |
| Baxter Healthcare | $18.89 | 2022 | |
| Urogen Pharma, INC. | $13.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Krishnamurthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.